COPD—beyond inhaler therapies with biologics

Debbie Rigby, advanced practice pharmacist Learning outcomes After completing this activity, pharmacists should be able to: describe the evolving role of type 2 inflammation and blood eosinophils in COPD; review the current evidence for biologic therapies in COPD; identify patients with COPD who may be appropriate candidates for biologic therapy. The 2016 Competency Standards addressed